Current assays fail to address breast cancer’s complex biology and accurately predict treatment response. On a retrospective cohort of 1082 female breast tissues, we develop and validate mFISHseq, which integrates multiplexed RNA fluorescent in situ hybridization with RNA-sequencing, guided by laser capture microdissection. This technique ensures tumor purity, unbiased whole transcriptome profiling, and explicitly quantifies intratumoral heterogeneity. Here we show mFISHseq has 93% accuracy compared to immunohistochemistry. Our consensus subtyping and risk groups mitigate single sample discordance, provide early and late prognostic information, and identify high risk patients with enriched immune signatures, which predict response to neoadjuvant immunotherapy in the multicenter, phase II, prospective I-SPY2 trial. We identify putative antibody-drug conjugate (ADC)-responsive patients, as evidenced by a 19-feature T-DM1 classifier, validated on I-SPY2. Deploying mFISHseq as a research-use only test on 48 patients demonstrates clinical feasibility, revealing insights into the efficacy of targeted therapies, like CDK4/6 inhibitors, immunotherapies, and ADCs.
The intensification of neoadjuvant therapy for early triple-negative breast cancer (eTNBC) – through the addition of carboplatin to standard chemotherapy and the incorporation of pembrolizumab – has markedly improved prognosis in recent years. However, this escalation carries a substantial risk of toxicity, and not all patients require the full regimen to achieve benefit. Realizing individualized treatment strategies will therefore depend on prognostic and predictive biomarkers that can forecast treatment response and long-term outcome. In the present study, we interrogated public gene expression datasets to develop transcriptomic signatures predicting response to neoadjuvant treatment and risk of recurrence. To validate these signatures, we used the Multiplex8+ platform for spatially informed comprehensive transcriptomic profiling in a real-world, multicenter, retrospective cohort of 590 patients diagnosed with eTNBC and treated with neoadjuvant chemotherapy with or without immunotherapy. The diagnostic Multiplex8+ test uses H&E and multiplexed RNA-FISH to guide the selection of specific tumor areas for the whole transcriptome sequencing and signature analysis. In the real-world cohort, the Multiplex8+ signatures were associated with both response and prognosis, remaining highly significant in multivariable models that included clinical parameters. The signatures were complementary to established biomarkers such as stromal tumor-infiltrating lymphocytes. These findings warrant prospective integration of the signatures into risk-stratified clinical trials to support future de-escalation and escalation strategies, enabling a better balance of efficacy, toxicity, cost, and drug availability.